Revenue: As of FY2026 Q2, the actual value is USD 47.28 M, missing the estimate of USD 49.1 M.

EPS: As of FY2026 Q2, the actual value is USD -0.16.

EBIT: As of FY2026 Q2, the actual value is USD -7.084 M.

Second Quarter 2026 Financial Highlights

Overall Performance

• Revenue: LifeMD, Inc. reported total revenue of $47.3 million for the second quarter of 2026, which was within the company’s guidance range of $47 million to $50 million. This represents a -4% decrease compared to $49.0 million in the prior-year period. Approximately 84% of this revenue was derived from recurring subscriptions.
• Adjusted EBITDA: The adjusted EBITDA loss was approximately - $3.5 million, an improvement of approximately 21% sequentially. This compares to an adjusted EBITDA of approximately $3.9 million in the prior-year period, marking a -191% year-over-year change.

Operational Metrics

• Gross Profit: Gross profit was $42.0 million, remaining essentially flat compared to $42.2 million in the prior-year period despite lower revenue.
• Gross Margin: Gross margin expanded to approximately 89% in Q2 2026, an increase of approximately 280 basis points from 86% in Q2 2025.
• Operating Loss from Continuing Operations: The operating loss from continuing operations was - $7,129,601 for Q2 2026, compared to - $2,346,886 for Q2 2025.
• Selling and Marketing Expenses: These expenses increased 27% year-over-year to $28.0 million but declined $1.8 million from the first quarter of 2026.
• General and Administrative Expenses: These expenses declined 5% to $13.6 million.
• GAAP Net Loss from Continuing Operations Attributable to Common Stockholders: The GAAP net loss from continuing operations attributable to common stockholders was - $7.9 million, or - $0.16 per share, for Q2 2026, compared to a GAAP net loss of - $3.8 million, or - $0.09 per share, in the prior-year period.

Cash Position

• Cash Balance: LifeMD, Inc. exited the quarter with $25.1 million in cash as of June 30, 2026, and reported no debt.
• Liquidity: The company had an undrawn $30 million revolving credit facility, providing additional liquidity.
• Net Cash Used in Operating Activities (Continuing Operations): Net cash used in operating activities from continuing operations was - $6,925,648 for Q2 2026, compared to $6,101,609 provided in Q2 2025.
• Net Cash Used in Investing Activities (Continuing Operations): Net cash used in investing activities from continuing operations was - $1,634,312 for Q2 2026, compared to - $2,836,983 for Q2 2025.
• Net Cash Used in Financing Activities (Continuing Operations): Net cash used in financing activities from continuing operations was - $776,562 for Q2 2026, compared to - $2,828,850 for Q2 2025.

Key Performance Indicators (KPIs)

• Total Active Subscribers: Total active subscribers increased 20% year-over-year to approximately 356,000 at quarter end.
• Weight Management Program Subscribers: The number of Weight Management Program subscribers grew to approximately 108,000 at quarter end, up from just under 100,000 at the end of the first quarter of 2026.
• GLP-1 Therapies: Approximately 95% of new weight management patients are now starting treatment with branded GLP-1 therapies.

Outlook and Guidance

LifeMD, Inc. expects a return to positive adjusted EBITDA in the second half of 2026 and projects a fourth-quarter exit revenue run rate of approximately $250 million annually with approximately $22 million of annualized adjusted EBITDA. For the full year 2026, the company revised its revenue guidance to a range of $205.5 million to $212.5 million and adjusted EBITDA guidance to - $6.0 million to breakeven, including launch costs for XYOSTED®. For the third quarter of 2026, revenue is expected to be in the range of $48 million to $51 million, with adjusted EBITDA in the range of - $1 million to positive $2 million.